Sign Out
There are no data on the safety of Lacidipine (Lacipil) in human pregnancy.
Animal studies have shown no teratogenic effects or growth impairment (see Toxicology: Pre-clinical Safety Data under Actions).
Lacidipine (Lacipil) should only be used in pregnancy when the potential benefits for the mother outweigh the possibility of adverse effects in the foetus or neonate.
The possibility that Lacidipine (Lacipil) can cause relaxation of the uterine muscle at term should be considered (see Toxicology: Pre-clinical Safety Data under Actions).
Milk transfer studies in animals have shown that lacidipine (or its metabolites) are likely to be excreted into breast milk.
Lacidipine (Lacipil) should only be used during lactation when the potential benefits for the mother outweigh the possibility of adverse effects in the foetus or neonate.
